- Home
- ENGN vs CTNM Comparison
ENGN vs CTNM Comparison
Compare ENGN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ENGN | CTNM |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 328.1M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | ENGN | CTNM |
|---|---|---|
| Price | $8.07 | $11.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $22.71 | $20.00 |
| AVG Volume (30 Days) | ★ 3.3M | 169.9K |
| Earning Date | 12-19-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $3.35 |
| 52 Week High | $11.14 | $15.25 |
Technical Indicators
Market Signals| Indicator | ENGN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 49.67 |
| Support Level | $7.65 | $10.42 |
| Resistance Level | $8.29 | $11.43 |
| Average True Range (ATR) | 0.63 | 0.80 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 76.79 | 28.10 |
Price Performance
Historical ComparisonAbout ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.